| Dr James A Goss, MD | |
|
3 Professional Park Dr, Suite 21, Johnson City, TN 37604-6529 | |
| (423) 434-6300 | |
| (423) 434-6312 |
| Full Name | Dr James A Goss |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 32 Years |
| Location | 3 Professional Park Dr, Johnson City, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295705549 | NPI | - | NPPES |
| 5903978 | Medicaid | NC | |
| 3808549 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 29075 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Johnson City Medical Center | Johnson city, TN | Hospital |
| Sycamore Shoals Hospital | Elizabethton, TN | Hospital |
| Unicoi County Hospital | Erwin, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Appalachian Orthopaedic Associates P C | 1052225471 | 37 |
News Archive
MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) in China for MRX-I, its first development-stage antibiotic drug candidate. MRX-I, an orally-administered oxazolidinone, targets multi-drug resistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
Verax Biomedical today announced that the company has gained FDA clearance to expand the use of its Verax Platelet PGD test—a rapid test for the detection of bacterial contamination in platelets intended for transfusion. The new FDA clearance makes the Verax Platelet PGD test the only rapid test on the market cleared by the FDA to check every commonly distributed platelet type in the United States.
In a new study that could improve the therapeutic efficacy of deep-brain stimulation for psychiatric disorders such as depression, a team of scientists shows that, when DBS is applied to a specific brain region, it improves patients' cognitive control over their behavior by increasing the power of a specific low-frequency brain rhythm in their prefrontal cortex.
An observational study by researchers at Mayo Clinic has found that increasing physical activity not only decreased the risk of death from all causes but also decreased the risk of death specifically from lymphoma.
› Verified 5 days ago
| Entity Name | Appalachian Orthopaedic Associates P C |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063875649 PECOS PAC ID: 1052225471 Enrollment ID: O20031126000433 |
News Archive
MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) in China for MRX-I, its first development-stage antibiotic drug candidate. MRX-I, an orally-administered oxazolidinone, targets multi-drug resistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
Verax Biomedical today announced that the company has gained FDA clearance to expand the use of its Verax Platelet PGD test—a rapid test for the detection of bacterial contamination in platelets intended for transfusion. The new FDA clearance makes the Verax Platelet PGD test the only rapid test on the market cleared by the FDA to check every commonly distributed platelet type in the United States.
In a new study that could improve the therapeutic efficacy of deep-brain stimulation for psychiatric disorders such as depression, a team of scientists shows that, when DBS is applied to a specific brain region, it improves patients' cognitive control over their behavior by increasing the power of a specific low-frequency brain rhythm in their prefrontal cortex.
An observational study by researchers at Mayo Clinic has found that increasing physical activity not only decreased the risk of death from all causes but also decreased the risk of death specifically from lymphoma.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr James A Goss, MD 3 Professional Park Dr, Suite 21, Johnson City, TN 37604-6529 Ph: (423) 434-6300 | Dr James A Goss, MD 3 Professional Park Dr, Suite 21, Johnson City, TN 37604-6529 Ph: (423) 434-6300 |
News Archive
MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) in China for MRX-I, its first development-stage antibiotic drug candidate. MRX-I, an orally-administered oxazolidinone, targets multi-drug resistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
Verax Biomedical today announced that the company has gained FDA clearance to expand the use of its Verax Platelet PGD test—a rapid test for the detection of bacterial contamination in platelets intended for transfusion. The new FDA clearance makes the Verax Platelet PGD test the only rapid test on the market cleared by the FDA to check every commonly distributed platelet type in the United States.
In a new study that could improve the therapeutic efficacy of deep-brain stimulation for psychiatric disorders such as depression, a team of scientists shows that, when DBS is applied to a specific brain region, it improves patients' cognitive control over their behavior by increasing the power of a specific low-frequency brain rhythm in their prefrontal cortex.
An observational study by researchers at Mayo Clinic has found that increasing physical activity not only decreased the risk of death from all causes but also decreased the risk of death specifically from lymphoma.
› Verified 5 days ago
Richard W Duncan, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2410 Susannah St, Johnson City, TN 37601 Phone: 423-282-9011 Fax: 423-282-0035 | |
Timothy Douglas Jenkins, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2410 Susannah Street, Johnson City, TN 37601 Phone: 423-282-9011 Fax: 423-282-0035 | |
Dr. David R Hardin, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 111 Pine Ct, Johnson City, TN 37601 Phone: 423-434-0014 Fax: 423-434-0014 | |
Dr. Jeffrey Alan Marchessault, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 410 N State Of Franklin Rd Ste 140, Johnson City, TN 37604 Phone: 423-431-2460 Fax: 423-431-2456 | |
Robert M Harris, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 410 N State Of Franklin Rd Ste 140, Johnson City, TN 37604 Phone: 423-431-2460 | |
Dr. Henry J. Williams, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 3 Professional Park Dr, Suite 21, Johnson City, TN 37604 Phone: 423-979-3333 Fax: 423-926-6713 | |
Dr. Thomas L Huddleston, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 3 Professional Park Dr, Suite 21, Johnson City, TN 37604 Phone: 423-434-6300 Fax: 423-434-6312 |